BPC
NVCR icon

Bryce Point Capital’s NovoCure NVCR Stock Holding History

Bryce Point Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$633K Buy
+48,975
New +$654K 0.77% 26

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bryce Point Capital's NVCR Position: Q3 2025 in Review

Bryce Point Capital opened a new position in NovoCure (NVCR) in Q3 2025: 48,975 shares worth $633K. The stake represents 0.77% of the portfolio and ranks #26 among its holdings.

244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Bryce Point Capital held 48,975 shares of NovoCure worth $633K as of Q3 2025.
  • NovoCure was a new Bryce Point Capital position in Q3 2025.
  • NovoCure made up 0.77% of Bryce Point Capital's portfolio in Q3 2025, its #26 holding.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.